About us
- >
- About us >
- Information >
- Announcement
2022-07-25
Energenesis Biomedical has obtained US patent for developing AMPK activation technology for the treatment of human inflammatory diseases.
We are thrilled to announce that our application for a patent on the medication developed using AMPK technology to treat human inflammatory diseases has been approved after thorough examination. The patent application number is 16/419,884.